Clinical Trial Update: A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Lund University Hospital | Conditions: Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED